This newly revealed CREB5/TOP1MT signal axis has provided a novel target for cisplatin resistance in HNSCC, which is of great significance for overcoming resistance and improving clinical efficacy. This evidence concerns the gene CREB5 and head and neck squamous cell carcinoma.